Zhang Joanne Y, Fabricant Peter D, Ishmael Chad R, Wang Jeffrey C, Petrigliano Frank A, Jones Kristofer J
Department of Orthopaedic Surgery, Boston Medical Center, Boston, Massachusetts, USA.
Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, New York, USA.
Orthop J Sports Med. 2016 Dec 21;4(12):2325967116676241. doi: 10.1177/2325967116676241. eCollection 2016 Dec.
Platelet-rich plasma (PRP) has emerged as a popular biologic treatment for musculoskeletal injuries and conditions. Despite numerous investigations on the efficacy of PRP therapy, current utilization of this treatment within the United States is not widely known.
To investigate the national utilization of PRP, including the incidence and conditions for which it is used in the clinical setting, and to determine the current charges associated with this treatment.
Descriptive epidemiology study.
Using a national database (PearlDiver) of private insurance billing records, we conducted a comprehensive search using Current Procedural Terminology (CPT) codes to identify patients who received PRP injections over a 2-year period (2010-2011). Associated International Classification of Diseases, 9th Revision (ICD-9) codes were identified to determine the specific conditions the injection was used to treat. The aggregate patient data were analyzed by yearly quarter, practice setting, geographic region, and demographics. PRP therapy charges were calculated and reported as per-patient average charges (PPACs).
A total of 2571 patients who received PRP injections were identified; 51% were male and 75% were older than 35 years. The overall incidence ranged from 5.9 to 7.9 per 1000 patients over the study period. PRP was most commonly administered in hospitals (39%) and ambulatory surgical centers (37%) compared with in private offices (26%). The most common conditions treated were knee meniscus/plica disorders, followed by unspecified shoulder conditions, rotator cuff injuries, epicondylitis, and plantar fasciitis. Further evaluation revealed that 25% of all patients received injections for cartilage-related conditions, 25% meniscus, 25% unspecified, 12% tendon, 8% glenoid labrum, and 5% ligament. The PPAC for PRP treatment was US$1755 per injection.
Despite a lack of consensus regarding PRP indications and efficacy, we observed widespread application of this treatment for a myriad of musculoskeletal injuries. Most treated patients were older than 35 years, and the most commonly treated conditions included cartilage and meniscus disorders. Given the current controversy surrounding this treatment, further studies are necessary to guide clinicians on the value of this therapy for each clinical diagnosis.
富含血小板血浆(PRP)已成为治疗肌肉骨骼损伤和病症的一种常用生物疗法。尽管对PRP疗法的疗效进行了大量研究,但目前该疗法在美国的使用情况尚不广为人知。
调查PRP在全国的使用情况,包括其在临床环境中的使用发病率和病症,并确定与该治疗相关的当前费用。
描述性流行病学研究。
利用一个包含私人保险计费记录的全国性数据库(PearlDiver),我们使用当前程序术语(CPT)代码进行了全面搜索,以识别在2年期间(2010 - 2011年)接受PRP注射的患者。确定相关的国际疾病分类第九版(ICD - 9)代码,以确定注射用于治疗的具体病症。按年度季度、执业环境、地理区域和人口统计学对汇总的患者数据进行分析。计算PRP治疗费用,并报告为每位患者的平均费用(PPAC)。
共识别出2571名接受PRP注射的患者;51%为男性,75%年龄超过35岁。在研究期间,总体发病率为每1000名患者5.9至7.9例。与私人诊所(26%)相比,PRP最常在医院(39%)和门诊手术中心(37%)使用。最常见的治疗病症是膝关节半月板/皱襞疾病,其次是未明确诊断的肩部疾病、肩袖损伤、上髁炎和足底筋膜炎。进一步评估显示,所有患者中有25%因软骨相关病症接受注射,25%因半月板病症,25%未明确诊断,12%因肌腱病症,8%因盂唇损伤,5%因韧带损伤。PRP治疗的PPAC为每次注射1755美元。
尽管关于PRP的适应症和疗效缺乏共识,但我们观察到该疗法广泛应用于多种肌肉骨骼损伤。大多数接受治疗的患者年龄超过35岁,最常见的治疗病症包括软骨和半月板疾病。鉴于目前围绕该疗法的争议,有必要进行进一步研究,以指导临床医生了解该疗法对每种临床诊断的价值。